Results 271 to 280 of about 130,693 (343)

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5527-5541, July 2026.
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Geremia B. Bolli, Philip D. Home, Mauro Lepore, Matthew C. Riddle, Francesca Porcellati, Carmine G. Fanelli, Paola Lucidi, Hannele Yki‐Järvinen, Reinhard H. Becker, David R. Owens   +9 more
wiley   +1 more source

Placenta Pathologies in Two Patients With Glycogen Storage Disease Type Ia and Preeclampsia. [PDF]

JIMD Rep
Laufs V, Hasenburg A, Busch MA, Lang F, Macchiella D, Mildenberger E, Seidmann L, Hennermann JB.   +7 more
europepmc   +1 more source

Periodontitis and Periodontal Conditions in Systemically Healthy Children and Adolescents

Journal of Clinical Periodontology, Volume 53, Issue 7, Page 1100-1198, July 2026.
ABSTRACT Objective To answer the PICoS question ‘in systemically healthy children and adolescents (Population), what are the main features of periodontitis, necrotising periodontal diseases (NPD) and other periodontal conditions (periodontal abscesses, endo‐periodontal lesions, traumatic occlusal forces, prosthesis‐ and tooth‐related factors ...
Inbar Eshkol‐Yogev, Nagore Ambrosio, Cheryl Somani, Elena Figuero, Lior Shapira, Janet Davies   +5 more
wiley   +1 more source

Growth impairment in glycogen storage disease type I versus types III/VI/IX: a cross-sectional study. [PDF]

BMC Pediatr
Wu X, Sun Y, Yang M.
europepmc   +1 more source

Liver-Directed Gene Therapy Mitigates Early Nephropathy in Murine Glycogen Storage Disease Type Ia. [PDF]

J Inherit Metab Dis
Lee C, Pratap K, Zhang L, Chen HD, Arnaoutova I, Starost MF, Mansfield BC, Chou JY.   +7 more
europepmc   +1 more source

Physical exercise intervention in glycogen storage disease IIIa: Feasibility and multisystem benefits. [PDF]

Exp Physiol
Bustos-Sellers A, Montalvo-Pérez A, Boraita A, Saco-Ledo G, Alejo LB, Barranco-Gil D, Valenzuela PL, López-Maldonado N, Ferrer-Costa R, Esparcia-Estrela J, Monteagudo-López C, Pinós T, Santos-Lozano A, Lucia A, Santalla A.   +14 more
europepmc   +1 more source

Galectin-3: a novel biomarker of glycogen storage disease type III. [PDF]

Cell Death Discov
Rossiaud L, Miagoux Q, Benabides M, Reiss O, Jauze L, Jarrige M, Polvèche H, Malfatti E, Laforêt P, Ronzitti G, Nissan X, Hoch L.   +11 more
europepmc   +1 more source

Interaction between neuromuscular junction metabolic requirements in fragile X syndrome and glycogen storage disease models. [PDF]

Dis Model Mech
Gurijala A, Rushton E, Leahy SN, Nelson N, Tessier CR, Broadie K.   +5 more
europepmc   +1 more source

Infant Born With Autosomal Recessive Glycogen Storage Disease Type IV due to Complete Maternal Isodisomy of Chromosome 3. [PDF]

Case Rep Genet
Olsen SS, Ernst A, Christensen PS, Björnsdóttir ED, Mark LR, Stefansen AV, Højland AT.   +6 more
europepmc   +1 more source

Hyperammonemia associated with glycogen storage disease type I

The Turkish Journal of Pediatrics, 1982
M Tunçer, H Yalçin, I Ozalp, M Cağlar
doaj